Cargando…

Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction?

Background: The United States Centers for Disease Control and Prevention (CDC) estimates a total obesity rate of 30% for 12 states and a 20% obesity rate nationwide. The obesity epidemic continues to increase in spite of preventative measures undertaken worldwide. Pharmacological treatments promise...

Descripción completa

Detalles Bibliográficos
Autores principales: Blum, Kenneth, Gold, Mark S., Llanos-Gomez, Luis, Jalali, Rehan, Thanos, Panayotis K., Bowirrat, Abdalla, Downs, William B., Bagchi, Debasis, Braverman, Eric R., Baron, David, Roy, Alphonso Kenison, Badgaiyan, Rajendra D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470221/
https://www.ncbi.nlm.nih.gov/pubmed/34574696
http://dx.doi.org/10.3390/ijerph18189774
_version_ 1784574143151210496
author Blum, Kenneth
Gold, Mark S.
Llanos-Gomez, Luis
Jalali, Rehan
Thanos, Panayotis K.
Bowirrat, Abdalla
Downs, William B.
Bagchi, Debasis
Braverman, Eric R.
Baron, David
Roy, Alphonso Kenison
Badgaiyan, Rajendra D.
author_facet Blum, Kenneth
Gold, Mark S.
Llanos-Gomez, Luis
Jalali, Rehan
Thanos, Panayotis K.
Bowirrat, Abdalla
Downs, William B.
Bagchi, Debasis
Braverman, Eric R.
Baron, David
Roy, Alphonso Kenison
Badgaiyan, Rajendra D.
author_sort Blum, Kenneth
collection PubMed
description Background: The United States Centers for Disease Control and Prevention (CDC) estimates a total obesity rate of 30% for 12 states and a 20% obesity rate nationwide. The obesity epidemic continues to increase in spite of preventative measures undertaken worldwide. Pharmacological treatments promise to reduce total fat mass. However, medications may have significant side effects and can be potentially fatal. Data Retrieval: This brief review, based on a PUBMED search of the key terms “Obesity” and” Sarcopenia,” will present evidence to corroborate the existence of Reward Deficiency Syndrome (RDS) in obesity and the involvement of catecholaminergic pathways in substance seeking behavior, particularly as it relates to carbohydrates cravings. Expert Opinion: The genetic basis and future genetic testing of children for risk of aberrant generalized craving behavior are considered a prevention method. Here we present evidence supporting the use of precursor amino acid therapy and modulation of enkephalinase, MOA, and COMT inhibition in key brain regions. Such treatments manifest in improved levels of dopamine/norepinephrine, GABA, serotonin, and enkephalins. We also present evidence substantiating insulin sensitivity enhancement via Chromium salts, which affect dopamine neuronal synthesis regulation. We believe our unique combination of natural ingredients will influence many pathways leading to the promotion of well-being and normal healthy metabolic functioning. Sarcopenia has been shown to reduce angiogenesis and possible cerebral blood flow. Exercise seems to provide a significant benefit to overcome this obesity-promoting loss of muscle density. Conclusion: Utilization of proposed nutrigenomic formulae based on coupling genetic obesity risk testing promotes generalized anti-craving of carbohydrates and can inhibit carbohydrate bingeing, inducing significant healthy fat loss and relapse prevention.
format Online
Article
Text
id pubmed-8470221
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84702212021-09-27 Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction? Blum, Kenneth Gold, Mark S. Llanos-Gomez, Luis Jalali, Rehan Thanos, Panayotis K. Bowirrat, Abdalla Downs, William B. Bagchi, Debasis Braverman, Eric R. Baron, David Roy, Alphonso Kenison Badgaiyan, Rajendra D. Int J Environ Res Public Health Article Background: The United States Centers for Disease Control and Prevention (CDC) estimates a total obesity rate of 30% for 12 states and a 20% obesity rate nationwide. The obesity epidemic continues to increase in spite of preventative measures undertaken worldwide. Pharmacological treatments promise to reduce total fat mass. However, medications may have significant side effects and can be potentially fatal. Data Retrieval: This brief review, based on a PUBMED search of the key terms “Obesity” and” Sarcopenia,” will present evidence to corroborate the existence of Reward Deficiency Syndrome (RDS) in obesity and the involvement of catecholaminergic pathways in substance seeking behavior, particularly as it relates to carbohydrates cravings. Expert Opinion: The genetic basis and future genetic testing of children for risk of aberrant generalized craving behavior are considered a prevention method. Here we present evidence supporting the use of precursor amino acid therapy and modulation of enkephalinase, MOA, and COMT inhibition in key brain regions. Such treatments manifest in improved levels of dopamine/norepinephrine, GABA, serotonin, and enkephalins. We also present evidence substantiating insulin sensitivity enhancement via Chromium salts, which affect dopamine neuronal synthesis regulation. We believe our unique combination of natural ingredients will influence many pathways leading to the promotion of well-being and normal healthy metabolic functioning. Sarcopenia has been shown to reduce angiogenesis and possible cerebral blood flow. Exercise seems to provide a significant benefit to overcome this obesity-promoting loss of muscle density. Conclusion: Utilization of proposed nutrigenomic formulae based on coupling genetic obesity risk testing promotes generalized anti-craving of carbohydrates and can inhibit carbohydrate bingeing, inducing significant healthy fat loss and relapse prevention. MDPI 2021-09-16 /pmc/articles/PMC8470221/ /pubmed/34574696 http://dx.doi.org/10.3390/ijerph18189774 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Blum, Kenneth
Gold, Mark S.
Llanos-Gomez, Luis
Jalali, Rehan
Thanos, Panayotis K.
Bowirrat, Abdalla
Downs, William B.
Bagchi, Debasis
Braverman, Eric R.
Baron, David
Roy, Alphonso Kenison
Badgaiyan, Rajendra D.
Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction?
title Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction?
title_full Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction?
title_fullStr Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction?
title_full_unstemmed Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction?
title_short Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction?
title_sort hypothesizing nutrigenomic-based precision anti-obesity treatment and prophylaxis: should we be targeting sarcopenia induced brain dysfunction?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470221/
https://www.ncbi.nlm.nih.gov/pubmed/34574696
http://dx.doi.org/10.3390/ijerph18189774
work_keys_str_mv AT blumkenneth hypothesizingnutrigenomicbasedprecisionantiobesitytreatmentandprophylaxisshouldwebetargetingsarcopeniainducedbraindysfunction
AT goldmarks hypothesizingnutrigenomicbasedprecisionantiobesitytreatmentandprophylaxisshouldwebetargetingsarcopeniainducedbraindysfunction
AT llanosgomezluis hypothesizingnutrigenomicbasedprecisionantiobesitytreatmentandprophylaxisshouldwebetargetingsarcopeniainducedbraindysfunction
AT jalalirehan hypothesizingnutrigenomicbasedprecisionantiobesitytreatmentandprophylaxisshouldwebetargetingsarcopeniainducedbraindysfunction
AT thanospanayotisk hypothesizingnutrigenomicbasedprecisionantiobesitytreatmentandprophylaxisshouldwebetargetingsarcopeniainducedbraindysfunction
AT bowirratabdalla hypothesizingnutrigenomicbasedprecisionantiobesitytreatmentandprophylaxisshouldwebetargetingsarcopeniainducedbraindysfunction
AT downswilliamb hypothesizingnutrigenomicbasedprecisionantiobesitytreatmentandprophylaxisshouldwebetargetingsarcopeniainducedbraindysfunction
AT bagchidebasis hypothesizingnutrigenomicbasedprecisionantiobesitytreatmentandprophylaxisshouldwebetargetingsarcopeniainducedbraindysfunction
AT bravermanericr hypothesizingnutrigenomicbasedprecisionantiobesitytreatmentandprophylaxisshouldwebetargetingsarcopeniainducedbraindysfunction
AT barondavid hypothesizingnutrigenomicbasedprecisionantiobesitytreatmentandprophylaxisshouldwebetargetingsarcopeniainducedbraindysfunction
AT royalphonsokenison hypothesizingnutrigenomicbasedprecisionantiobesitytreatmentandprophylaxisshouldwebetargetingsarcopeniainducedbraindysfunction
AT badgaiyanrajendrad hypothesizingnutrigenomicbasedprecisionantiobesitytreatmentandprophylaxisshouldwebetargetingsarcopeniainducedbraindysfunction